161 related articles for article (PubMed ID: 37530704)
21. Advances in prostate-specific membrane antigen PET of prostate cancer.
Bouchelouche K; Choyke PL
Curr Opin Oncol; 2018 May; 30(3):189-196. PubMed ID: 29465429
[TBL] [Abstract][Full Text] [Related]
22. Robot-Assisted Prostate-Specific Membrane Antigen-Radioguided Surgery in Primary Diagnosed Prostate Cancer.
Gondoputro W; Scheltema MJ; Blazevski A; Doan P; Thompson JE; Amin A; Geboers B; Agrawal S; Siriwardana A; Van Leeuwen PJ; van Oosterom MN; Van Leeuwen FWB; Emmett L; Stricker PD
J Nucl Med; 2022 Nov; 63(11):1659-1664. PubMed ID: 35241483
[TBL] [Abstract][Full Text] [Related]
23. Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study.
Donswijk ML; van Leeuwen PJ; Vegt E; Cheung Z; Heijmink SWTPJ; van der Poel HG; Stokkel MPM
BMC Cancer; 2020 Aug; 20(1):723. PubMed ID: 32758168
[TBL] [Abstract][Full Text] [Related]
24. Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer: a novel technology to detect lymph node metastases.
Maurer T; Gschwend JE; Eiber M
Curr Opin Urol; 2018 Mar; 28(2):191-196. PubMed ID: 29028767
[TBL] [Abstract][Full Text] [Related]
25. Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit.
Maestroni UV; Campobasso D; Guarino G; Acampora A; Scarlattei M; Ziglioli F; Dinale F; Baldari G; Migliari S; Gasparro D; Ferretti S; Silini EM; Ruffini L
Chin Clin Oncol; 2023 Jun; 12(3):22. PubMed ID: 37417288
[TBL] [Abstract][Full Text] [Related]
26. EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [
Fanti S; Briganti A; Emmett L; Fizazi K; Gillessen S; Goffin K; Hadaschik BA; Herrmann K; Kunikowska J; Maurer T; MacLennan S; Mottet N; Murphy DG; Oprea-Lager DE; O'Sullivan JM; Oyen WJG; Rouvière O; Sartor O; Stenzl A; Van Poppel H; Walz J; Witjes W; Bjartell A
Eur Urol Oncol; 2022 Oct; 5(5):530-536. PubMed ID: 35697600
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
28. Will
Cuccurullo V; di Stasio GD; Evangelista L; Ciarmiello A; Mansi L
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):103-109. PubMed ID: 29422356
[TBL] [Abstract][Full Text] [Related]
29. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
Rowe SP; Gorin MA; Allaf ME; Pienta KJ; Tran PT; Pomper MG; Ross AE; Cho SY
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):223-30. PubMed ID: 27136743
[TBL] [Abstract][Full Text] [Related]
30. Radiolabeled prostate-specific membrane antigen small-molecule inhibitors.
Will L; Sonni I; Kopka K; Kratochwil C; Giesel FL; Haberkorn U
Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):168-180. PubMed ID: 28217987
[TBL] [Abstract][Full Text] [Related]
31. [
Evangelista L; Maurer T; van der Poel H; Alongi F; Kunikowska J; Laudicella R; Fanti S; Hofman MS
Eur Urol Oncol; 2022 Jun; 5(3):273-282. PubMed ID: 35367165
[TBL] [Abstract][Full Text] [Related]
32. High negative predictive value of 68Ga PSMA PET-CT for local lymph node metastases in high risk primary prostate cancer with histopathological correlation.
Rahman LA; Rutagengwa D; Lin P; Lin M; Yap J; Lai K; Mancuso P; Rathore P; Haghighi K; Gassner P; Wong LH; Lalak N
Cancer Imaging; 2019 Dec; 19(1):86. PubMed ID: 31829288
[TBL] [Abstract][Full Text] [Related]
33. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
Perera M; Papa N; Roberts M; Williams M; Udovicich C; Vela I; Christidis D; Bolton D; Hofman MS; Lawrentschuk N; Murphy DG
Eur Urol; 2020 Apr; 77(4):403-417. PubMed ID: 30773328
[TBL] [Abstract][Full Text] [Related]
34. Potential Impact of
Calais J; Kishan AU; Cao M; Fendler WP; Eiber M; Herrmann K; Ceci F; Reiter RE; Rettig MB; Hegde JV; Shaverdian N; King CR; Steinberg ML; Czernin J; Nickols NG
J Nucl Med; 2018 Nov; 59(11):1714-1721. PubMed ID: 29653978
[TBL] [Abstract][Full Text] [Related]
35. [Positron emission tomography with computed tomography/magnetic resonance imaging for primary staging of prostate cancer].
Hasa E; Langbein T; Eiber M; Knorr K
Radiologe; 2021 Sep; 61(9):818-824. PubMed ID: 34351430
[TBL] [Abstract][Full Text] [Related]
36. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
37. Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer.
Farolfi A; Calderoni L; Mattana F; Mei R; Telo S; Fanti S; Castellucci P
J Nucl Med; 2021 May; 62(5):596-604. PubMed ID: 33712536
[TBL] [Abstract][Full Text] [Related]
38. Baseline PSMA-PET/CT as a predictor of PSA persistence following radical prostatectomy in high-risk nonmetastatic prostate cancer patients receiving neoadjuvant therapy.
Du X; Dong Y; Liu J; Su Y; Zhu Y; Pan J; Dong B; Chen R; Liu J; Tong Z; Pienta KJ; Rowe SP; Dong L; Xue W
Prostate; 2023 Aug; 83(11):1112-1120. PubMed ID: 37165552
[TBL] [Abstract][Full Text] [Related]
39. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.
Hofman MS; Iravani A
PET Clin; 2017 Apr; 12(2):219-234. PubMed ID: 28267455
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
Jilg CA; Drendel V; Rischke HC; Beck T; Vach W; Schaal K; Wetterauer U; Schultze-Seemann W; Meyer PT
Theranostics; 2017; 7(6):1770-1780. PubMed ID: 28529650
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
